Alumis Inc

ALMS · NASDAQ · Healthcare / Biotechnology

5.60USD-0.53 (-8.65%)

Price History

Full chart

Market Stats

Previous Close6.13

Open6.04

Day Range5.52 – 6.10

52-Week Range3.76 – 31.35

Volume1.49M

Market Cap918.99M

P/E (TTM)0.00

Forward P/E0.00

EPS-4.12

Dividend Yield0.00%

Beta-0.79

50-Day Avg20.27

200-Day Avg22.26

About

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Martin Babler Ph.D.
Employees237
Headquarters280 East Grand Avenue, South San Francisco, CA, United States, 94080, USA
Websitehttps://www.alumis.com

Leadership

Mr. Martin Babler Ph.D.President, CEO & Chairman · b. 1965
Dr. David M. Goldstein Ph.D.Chief Scientific Officer · b. 1966
Dr. Jorn Drappa M.D., Ph.D.Chief Medical Officer & Head of Research and Development · b. 1965
Mr. John R. Schroer C.F.A.Chief Financial Officer · b. 1965
Ms. Sanam Pangali J.D.Chief Legal Officer & Corporate Secretary · b. 1984
Mr. Roy C. Hardiman J.D.Chief Business & Strategy Officer · b. 1960
Ms. Claire Langrish Ph.D.Senior VP & Head of Immunology and Translational Science
Mr. Philip Nunn Ph.D.Senior VP of Pharmacology & Project Team Leader
Mr. Mark BradleyChief Development Officer · b. 1966
Mr. Kolbot By Ph.D.Senior VP & Head of Technical Operations

Financials

Income Statement

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	24.05M
Cost of Revenue	250.00K	1.28M	3.15M	3.50M
Gross Profit	-250.00K	-1.28M	-3.15M	20.55M
Gross Margin	-	-	-	85.46%
Operating Expense	113.60M	156.89M	297.60M	447.76M
Operating Income	-113.85M	-158.17M	-300.75M	-427.20M
Operating Margin	-	-	-	-1776.32%
EBITDA	-111.68M	-153.71M	-291.08M	-248.39M
EBITDA Margin	-	-	-	-1032.81%
Net Income	-111.93M	-154.99M	-294.23M	-243.32M
Net Income Margin	-	-	-	-1011.75%
R&D	101.05M	137.68M	265.55M	386.00M
R&D as % of Total Revenue	-	-	-	1604.98%

Balance Sheet

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	108.17M	89.61M	340.99M	411.94M
Total Liabilities	303.41M	428.87M	80.89M	110.64M
Total Equity	-195.24M	-339.26M	260.10M	301.30M
Cash	25.61M	46.00M	169.53M	89.67M
Total Debt	1.78M	32.58M	30.72M	36.91M
Net Debt	-23.83M	-13.42M	-138.80M	-52.76M

Cash Flow

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-107.72M	-129.97M	-255.08M	-369.52M
Investing Cash Flow	-68.75M	60.47M	-113.79M	287.88M
Financing Cash Flow	101.63M	89.68M	492.37M	2.07M
Capital Expenditure	2.41M	4.50M	1.73M	653.00K
Free Cash Flow	-110.13M	-134.47M	-256.81M	-370.18M
FCF to OCF	102.23%	103.46%	100.68%	100.18%

Earnings

Report Date	May 29, 2024	Aug 13, 2024	Nov 13, 2024	Mar 19, 2025	May 14, 2025	Aug 13, 2025	Nov 13, 2025	Mar 19, 2026	May 14, 2026	Aug 13, 2026	Nov 12, 2026
EPS Estimate	0.00	-1.67	-1.72	-1.32	-1.42	-1.39	-0.92	-0.98	-0.77	-0.70	-0.73
EPS Actual	-4.50	-22.16	-1.73	-1.74	-1.82	-1.47	-1.06	-0.25	-0.74	-0.78	-
Surprise	-	-1226.95%	-0.58%	-31.82%	-28.17%	-5.76%	-15.22%	74.49%	3.90%	-11.43%	-
Timing	-	After-hours	After-hours	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours

Key Statistics & Ratios

Market Cap918.99M

Enterprise Value526.00M

Trailing P/E0.00

Forward P/E0.00

Price / Sales124.22

Price / Book2.13

EPS-4.12

Book Value3.52

Revenue (TTM)7.40M

Gross Profit (TTM)7.40M

EBITDA-421.45M

Profit Margin0.00%

Operating Margin-6439.89%

Return on Equity-93.65%

Return on Assets-45.34%

Shares Outstanding129.44M

Shares Float97.16M

Beta-0.79

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 6 analystsTarget 32.13

Strong Buy
4
Buy
2

Ownership Breakdown

Institutions: 93.66%
Insiders: 0.53%
Retail / Other: 5.81%

Top Institutional Holders

BlackRock Inc
7.17M5.54%
Deep Track Capital, LP
6.35M4.90%
Samsara BioCapital, LLC
6.35M4.90%
Foresite Capital Management V, LLC
5.90M4.56%
venBio Partners LLC
4.53M3.50%
Foresite Capital Management VI LLC
4.25M3.28%
Vanguard Capital Management, LLC
4.03M3.12%
Cormorant Asset Management, LLC
3.95M3.05%
Nextech Invest, Ltd.
3.54M2.74%
T. Rowe Price Associates, Inc.
3.29M2.54%
UBS Group AG
3.05M2.36%
Saturn V Capital Management LLC
2.92M2.25%
Octagon Capital Advisors LP
2.83M2.19%
HHG PLC
2.12M1.64%
MPM Oncology Impact Management LP
2.02M1.56%
Baker Bros Advisors LP
2.01M1.55%
SR ONE CAPITAL MANAGEMENT, LP
1.96M1.51%
Geode Capital Management, LLC
1.92M1.48%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
3.15M2.43%
iShares Russell 2000 ETF
2.03M1.57%